Mentor  Pharmaceutical Consulting



MPC has developed a new delivery formulation for topical delivery of vitamin B12

MPC has identified a new topical formulation for treatment of various inflammatory diseases including multiple sclerosis, Parkinson's disease, Crohn's disease, arthritis, psoriasis, eczema, ulcerative colitis.

MPC has identified the biochemical basis of the debilitating condition, chronic fatigue syndrome.

MPC has identified the biochemical basis for development of Autism Spectrum disorder.

MPC has identified a number of new targeting molecules suitable for oral protein delivery.

MPC has identified a new method for oral delivery of antibody molecules and antibody Fc-fusions.

MPC has identified a novel method for oral delivery of insulin and IGF.

MPC has identified a novel serum diagnostic to detect breast, ovarian, prostate and lung cancer.

MPC has identified a novel vehicle for dissolution of Class II poorly soluble drugs

Each of the systems identified are available for license, co-license, or co-development.

Recent Publications

Russell-Jones, G. J. McTavish, K. J., McEwan, J. F., Thurmond, B. 2012  Increasing the tumoricidal activity of daunomycin-pHPMA conjugates using vitamin B12 as a targeting agent.  J. Cancer Research Updates, 1, 203-211 PDF

Russell-Jones, G. J., McTavish, K. J. McEwan, J.F. 2011 Preliminary Studies on the Selective Accumulation of Vitamin-Targeted Polymers Within Tumours. J. Drug Targ. 19, 133-9 PDF ColourFigs

Russell-Jones, G. J. and Himes, R. 2011 Water-in-oil Microemulsions for Effective Transdermal Delivery of Proteins. Expert Opinion in Drug Delivery. Invited review   8, 537-546. PDF

Himes, R., Lee, S., McMenigall, K. and Russell-Jones, G. 2011 The influence of molecular adjuvants in the cutaneous response to antigen after topical vaccination. Vaccine, June 12, 29, 5393-8 PDF

Russell-Jones, G. J. 2011 Intestinal receptor targeting for peptide delivery: Reasons for failure and new opportunities. Invited Review. Therapeutic Delivery 2, 12, 1575-1593. PDF